Feedback / Questions
FKB238 (bevacizumab biosimilar) - Fujifilm Kyowa Kirin Biologics, AstraZeneca
Kyowa Hakko Kirin: Mid-term Business Plan
(Kyowa Hakko Kirin Pharma)
-
Feb 11, 2016 -
Anticipated approval in UK in 2016-2020
Anticipated EU regulatory
•
Biosimilar
http://www.kyowa-kirin.com/news_releases/2016/pdf/e20160204_01.pdf
Feb 11, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.